{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:13:05Z","timestamp":1793146385341,"version":"4.5.0"},"reference-count":55,"publisher":"American Association for Cancer Research (AACR)","issue":"2","license":[{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001238","name":"Merck & Co. | Merck Company Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031022","name":"HHS | NIH | NCI | Center for Cancer Research","doi-asserted-by":"publisher","award":["P30 CA012197"],"award-info":[{"award-number":["P30 CA012197"]}],"id":[{"id":"10.13039\/100031022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Single-agent checkpoint inhibition is effective in a minority of patients with platinum-refractory urothelial carcinoma; therefore, the efficacy of combining low-dose paclitaxel with pembrolizumab was tested.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>This was a prospective, single-arm phase II trial with key inclusion criteria of imaging progression within 12 months of platinum therapy and Eastern Cooperative Oncology Group \u22641. Treatment was pembrolizumab 200 mg day 1 and paclitaxel 80 mg\/m2 days 1 and 8 of a 21-day cycle for up to eight cycles unless progression or unacceptable adverse events (AE). The primary endpoint was overall response rate (ORR) with overall survival (OS), 6-month progression-free survival (PFS), and safety as key secondary endpoints. Change in circulating immune cell populations, plasma, and urinary miRs were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Twenty-seven patients were treated between April 2016 and June 2020, with median follow-up of 12.4 months. Baseline median age was 68 years, with 81% men and 78% non-Hispanic White. ORR was 33% by intention to treat and 36% in imaging-evaluable patients with three complete responses. Six-month PFS rate was 48.1% [95% confidence interval (CI): 28.7\u201365.2] and median OS 12.4 months (95% CI: 8.7 months to not reached). Common \u2265 grade 2 possibly-related AEs were anemia, lymphopenia, hyperglycemia, and fatigue; grade 3\/4 AEs occurred in 56%, including two immune-mediated AEs (pneumonitis and nephritis). Responding patients had a higher percentage of circulating CD4+IFN\u03b3+ T cells. Levels of some miRs, including plasma miR 181 and miR 223, varied in responders compared with nonresponders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The addition of low-dose paclitaxel to pembrolizumab is active and safe in platinum-refractory urothelial carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>We found that combining pembrolizumab with low-dose paclitaxel may be effective in patients with urothelial carcinoma progressing on platinum chemotherapy, with favorable safety profiles.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-23-0436","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T10:12:05Z","timestamp":1707732725000},"page":"530-539","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma"],"prefix":"10.1158","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5253-0551","authenticated-orcid":true,"given":"Rhonda L.","family":"Bitting","sequence":"first","affiliation":[{"name":"1Department of Internal Medicine, Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina."},{"name":"2Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5160-0407","authenticated-orcid":true,"given":"Janet A.","family":"Tooze","sequence":"additional","affiliation":[{"name":"2Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina."},{"name":"3Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6320-9707","authenticated-orcid":true,"given":"Michael","family":"Goodman","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine, Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina."},{"name":"2Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8660-1350","authenticated-orcid":true,"given":"Donald C.","family":"Vile","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine, Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9031-9987","authenticated-orcid":true,"given":"Jessica M.","family":"Brown","sequence":"additional","affiliation":[{"name":"4Department of Microbial Infection and Immunity, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4703-3536","authenticated-orcid":true,"given":"Christopher Y.","family":"Thomas","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine, Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina."},{"name":"2Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8076-6844","authenticated-orcid":true,"given":"Morgan","family":"Neve","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine, Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8340-6762","authenticated-orcid":true,"given":"Mitra","family":"Kooshki","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine, Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8252-653X","authenticated-orcid":true,"given":"Safoa","family":"Addo","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine, Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2488-6136","authenticated-orcid":true,"given":"Pierre L.","family":"Triozzi","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine, Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina."},{"name":"2Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5454-8421","authenticated-orcid":true,"given":"Purnima","family":"Dubey","sequence":"additional","affiliation":[{"name":"4Department of Microbial Infection and Immunity, The Ohio State University, Columbus, Ohio."},{"name":"5Pelotonia Institute of Immunooncology, James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,2,26]]},"reference":[{"key":"2024022614091713600_bib1","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"2024022614091713600_bib2","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"2024022614091713600_bib3","doi-asserted-by":"crossref","first-page":"e001246","DOI":"10.1136\/jitc-2020-001246","article-title":"Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis","volume":"8","author":"Apolo","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2024022614091713600_bib4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/annonc\/mdx686","article-title":"Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy","volume":"29","author":"Rotte","year":"2018","journal-title":"Ann Oncol"},{"key":"2024022614091713600_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br J Cancer"},{"key":"2024022614091713600_bib6","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.immuni.2005.02.003","article-title":"Primary antitumor immune response mediated by CD4+ T cells","volume":"22","author":"Corthay","year":"2005","journal-title":"Immunity"},{"key":"2024022614091713600_bib7","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1084\/jem.188.12.2357","article-title":"The central role of CD4(+) T cells in the antitumor immune response","volume":"188","author":"Hung","year":"1998","journal-title":"J Exp Med"},{"key":"2024022614091713600_bib8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer","volume":"41","author":"Hoimes","year":"2023","journal-title":"J Clin Oncol"},{"key":"2024022614091713600_bib9","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"2024022614091713600_bib10","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"key":"2024022614091713600_bib11","doi-asserted-by":"crossref","first-page":"S1155","DOI":"10.1016\/j.annonc.2020.08.2252","article-title":"LBA23 pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361","volume":"31","author":"Alva","year":"2020","journal-title":"Ann Oncol"},{"key":"2024022614091713600_bib12","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s11136-015-0966-y","article-title":"Dutch-Flemish translation of nine pediatric item banks from the Patient-Reported Outcomes Measurement Information System (PROMIS)(R)","volume":"25","author":"Haverman","year":"2016","journal-title":"Qual Life Res"},{"key":"2024022614091713600_bib13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4049\/jimmunol.0900734","article-title":"Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism","volume":"183","author":"Shurin","year":"2009","journal-title":"J Immunol"},{"key":"2024022614091713600_bib14","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-3083.2011.02514.x","article-title":"CD4+Foxp3+ regulatory T-cell impairment by paclitaxel is independent of toll-like receptor 4","volume":"73","author":"Zhu","year":"2011","journal-title":"Scand J Immunol"},{"key":"2024022614091713600_bib15","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2217\/imt-2017-0052","article-title":"Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy","volume":"9","author":"Zheng","year":"2017","journal-title":"Immunotherapy"},{"key":"2024022614091713600_bib16","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.4049\/jimmunol.1202781","article-title":"Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model","volume":"190","author":"Sevko","year":"2013","journal-title":"J Immunol"},{"key":"2024022614091713600_bib17","doi-asserted-by":"crossref","first-page":"44134","DOI":"10.18632\/oncotarget.6628","article-title":"Enhancement of adoptive T cell transfer with single low dose pretreatment of doxorubicin or paclitaxel in mice","volume":"6","author":"Hsu","year":"2015","journal-title":"Oncotarget"},{"key":"2024022614091713600_bib18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.juro.2006.08.078","article-title":"Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines","volume":"177","author":"Loskog","year":"2007","journal-title":"J Urol"},{"key":"2024022614091713600_bib19","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/ijc.26123","article-title":"Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer","volume":"130","author":"Eruslanov","year":"2012","journal-title":"Int J Cancer"},{"key":"2024022614091713600_bib20","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1189\/jlb.0310162","article-title":"Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties","volume":"89","author":"Brandau","year":"2011","journal-title":"J Leukoc Biol"},{"key":"2024022614091713600_bib21","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/j.1349-7006.2012.02248.x","article-title":"Immunosuppressive activity of CD14+ HLA-DR-cells in squamous cell carcinoma of the head and neck","volume":"103","author":"Chikamatsu","year":"2012","journal-title":"Cancer Sci"},{"key":"2024022614091713600_bib22","doi-asserted-by":"crossref","first-page":"11774","DOI":"10.1073\/pnas.1410626111","article-title":"Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells","volume":"111","author":"Kim","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024022614091713600_bib23","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/CJI.0b013e3181c01fcb","article-title":"Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy","volume":"33","author":"Mangsbo","year":"2010","journal-title":"J Immunother"},{"key":"2024022614091713600_bib24","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.5858\/arpa.2015-0544-OA","article-title":"Development of a prototype immunohistochemistry assay to measure programmed death ligand-1 expression in tumor tissue","volume":"140","author":"Dolled-Filhart","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"2024022614091713600_bib25","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"2024022614091713600_bib26","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jtho.2020.06.015","article-title":"A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2024022614091713600_bib27","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J Clin Oncol"},{"key":"2024022614091713600_bib28","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"2024022614091713600_bib29","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"key":"2024022614091713600_bib30","doi-asserted-by":"crossref","first-page":"S1254","DOI":"10.1016\/j.annonc.2023.10.107","article-title":"LBA7 \u2013 nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: results from the phase III CheckMate 901 trial","volume":"34","author":"van der Heijden","year":"2023","journal-title":"Ann Oncol"},{"key":"2024022614091713600_bib31","first-page":"S1254","article-title":"LBA6 - EV-302\/KEYNOTE-A39: open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab vs chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma","volume":"34","author":"Powles","year":"2023","journal-title":"Ann Oncol"},{"key":"2024022614091713600_bib32","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"2024022614091713600_bib33","doi-asserted-by":"crossref","first-page":"e007613","DOI":"10.1136\/jitc-2023-007613","article-title":"Antitumor immunity as the basis for durable disease-free treatment-free survival in patients with metastatic urothelial cancer","volume":"11","author":"Anker","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2024022614091713600_bib34","doi-asserted-by":"crossref","first-page":"S682","DOI":"10.1016\/j.annonc.2021.08.054","article-title":"658MO cisplatin (cis)-related immunomodulation and efficacy with atezolizumab (atezo) + cis- vs carboplatin (carbo)-based chemotherapy (chemo) in metastatic urothelial cancer (mUC)","volume":"32","author":"Galsky","year":"2021","journal-title":"Ann Oncol"},{"key":"2024022614091713600_bib35","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41419-020-2567-0","article-title":"Exploiting immune-dependent effects of microtubule-targeting agents to improve efficacy and tolerability of cancer treatment","volume":"11","author":"Serpico","year":"2020","journal-title":"Cell Death Dis"},{"key":"2024022614091713600_bib36","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/JU.0000000000002969","article-title":"A phase 2 trial of nab-paclitaxel in combination with anti-PD1 therapy in advanced urothelial cancer","volume":"209","author":"Tsung","year":"2023","journal-title":"J Urol"},{"key":"2024022614091713600_bib37","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.annonc.2020.09.012","article-title":"Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study","volume":"31","author":"Giannatempo","year":"2020","journal-title":"Ann Oncol"},{"key":"2024022614091713600_bib38","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1001\/jamaoncol.2019.2311","article-title":"Multiomics prediction of response rates to therapies to inhibit programmed cell death 1 and programmed cell death 1 ligand 1","volume":"5","author":"Lee","year":"2019","journal-title":"JAMA Oncol"},{"key":"2024022614091713600_bib39","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.cell.2020.05.017","article-title":"Intratumoral CD4(+) T cells mediate anti-tumor cytotoxicity in human bladder cancer","volume":"181","author":"Oh","year":"2020","journal-title":"Cell"},{"key":"2024022614091713600_bib40","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF01742372","article-title":"Recombinant human interferon gamma exerts an anti-proliferative effect and modulates the expression of human leukocyte antigens A,B,C and DR in human urothelial cell lines","volume":"31","author":"Ottesen","year":"1990","journal-title":"Cancer Immunol Immunother"},{"key":"2024022614091713600_bib41","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1464-410X.1989.tb05187.x","article-title":"HLA-DR expression by high grade superficial bladder cancer treated with BCG","volume":"63","author":"Prescott","year":"1989","journal-title":"Br J Urol"},{"key":"2024022614091713600_bib42","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.autrev.2009.01.008","article-title":"MicroRNAs: novel regulators of immunity","volume":"8","author":"Carissimi","year":"2009","journal-title":"Autoimmun Rev"},{"key":"2024022614091713600_bib43","doi-asserted-by":"crossref","first-page":"632329","DOI":"10.1155\/2012\/632329","article-title":"Natural killer cell regulation by microRNAs in health and disease","volume":"2012","author":"Leong","year":"2012","journal-title":"J Biomed Biotechnol"},{"key":"2024022614091713600_bib44","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.intimp.2010.11.004","article-title":"Invariant NKT cell development and function in microRNA-223 knockout mice","volume":"11","author":"Li","year":"2011","journal-title":"Int Immunopharmacol"},{"key":"2024022614091713600_bib45","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.immuni.2013.02.021","article-title":"The microRNA miR-181 is a critical cellular metabolic rheostat essential for NKT cell ontogenesis and lymphocyte development and homeostasis","volume":"38","author":"Henao-Mejia","year":"2013","journal-title":"Immunity"},{"key":"2024022614091713600_bib46","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.4049\/jimmunol.0803162","article-title":"Cutting edge: the Foxp3 target miR-155 contributes to the development of regulatory T cells","volume":"182","author":"Kohlhaas","year":"2009","journal-title":"J Immunol"},{"key":"2024022614091713600_bib47","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.cellimm.2009.10.012","article-title":"microRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients","volume":"260","author":"Hezova","year":"2010","journal-title":"Cell Immunol"},{"key":"2024022614091713600_bib48","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1002\/ijc.25921","article-title":"miR-223 suppresses differentiation of tumor-induced CD11b(+) Gr1(+) myeloid-derived suppressor cells from bone marrow cells","volume":"129","author":"Liu","year":"2011","journal-title":"Int J Cancer"},{"key":"2024022614091713600_bib49","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1158\/1541-7786.MCR-15-0147","article-title":"IL6 mediates immune and colorectal cancer cell cross-talk via miR-21 and miR-29b","volume":"13","author":"Patel","year":"2015","journal-title":"Mol Cancer Res"},{"key":"2024022614091713600_bib50","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1038\/s41388-018-0178-3","article-title":"miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy","volume":"37","author":"Xi","year":"2018","journal-title":"Oncogene"},{"key":"2024022614091713600_bib51","doi-asserted-by":"crossref","first-page":"5938688","DOI":"10.1155\/2022\/5938688","article-title":"Anti-PD-L1 antibody enhances T cell immune responses and reduces resistance of breast cancer cells to radiotherapy","volume":"2022","author":"Guo","year":"2022","journal-title":"Oxid Med Cell Longev"},{"key":"2024022614091713600_bib52","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1172\/JCI98060","article-title":"Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma","volume":"128","author":"Huber","year":"2018","journal-title":"J Clin Invest"},{"key":"2024022614091713600_bib53","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1158\/1078-0432.CCR-18-1981","article-title":"Circulating miRNAs and PD-L1 tumor expression are associated with survival in advanced NSCLC patients treated with immunotherapy: a prospective Study","volume":"25","author":"Boeri","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2024022614091713600_bib54","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.3390\/cancers12113396","article-title":"A \u201cLymphocyte MicroRNA Signature\u201d as predictive biomarker of immunotherapy response and plasma PD-1\/PD-L1 expression levels in patients with metastatic renal cell carcinoma: pointing towards epigenetic reprogramming","volume":"12","author":"Incorvaia","year":"2020","journal-title":"Cancers"},{"key":"2024022614091713600_bib55","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/1940-6207.CAPR-11-0370","article-title":"Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies","volume":"5","author":"Pritchard","year":"2012","journal-title":"Cancer Prev Res"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-23-0436\/3414641\/crc-23-0436.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/2\/530\/3419402\/crc-23-0436.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/2\/530\/3419402\/crc-23-0436.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T09:09:53Z","timestamp":1708938593000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/4\/2\/530\/734916\/Low-dose-Paclitaxel-with-Pembrolizumab-Enhances"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,26]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,26]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-23-0436","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7091750","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.7091750.v1","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.25288985.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25288991.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25288970.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25288991","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25288976.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25288979.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25288973.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25288985","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25288976","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25288988","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25288970","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25288982","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25288973","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25288982.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25288979","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25288988.v1","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,26]]}}}